New combo therapy aims to silence hepatitis b virus
NCT ID NCT07069569
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tests whether adding an experimental drug (AHB-137) to either a hepatitis B vaccine or an immune-boosting medicine (pegylated interferon) can help people with chronic hepatitis B stop their daily antiviral pills without the virus coming back. About 127 adults with HBeAg-negative chronic hepatitis B who are already on standard antiviral therapy will take part. The main goal is to see if the virus stays undetectable 24 weeks after all treatments are stopped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.